Resumen
Patients with adenoid cystic carcinoma (ACC) often experience late distant metastasis years after definitive therapy, most commonly to the lungs. Currently, there is little consensus on the optimal treatment regimens for metastatic ACC, which typically confer modest clinical benefit. Here, we outline management approaches for metastatic ACC in the context of pertinent ACC biology. We summarize the most commonly utilized systemic treatment regimens, review methods of local control for oligometastatic lung disease, and highlight emerging molecular targets with promise for advancing ACC management in the future.